Outcomes and management of primary tumors in metastatic MSI/dMMR colorectal cancer patients treated with immune checkpoint inhibitors: a cohort study.

L Mas, C Grosnon, T Samaille, A Dardenne, Y Parc, J Lefèvre, R Cohen, T André

Abstract read

In one paragraph

Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

L MasDepartment of Medical Oncology, Sorbonne University, Hôpital Saint-Antoine, AP-HP, Paris, France.

C GrosnonDepartment of Medical Oncology, Sorbonne University, Hôpital Saint-Antoine, AP-HP, Paris, France.

T SamailleDepartment of Medical Oncology, Sorbonne University, Hôpital Saint-Antoine, AP-HP, Paris, France.

A DardenneDepartment of Medical Oncology, Sorbonne University, Hôpital Saint-Antoine, AP-HP, Paris, France.

Y ParcDepartment of Digestive Surgery, Sorbonne University, Hôpital Saint-Antoine, AP-HP, Paris, France.

J LefèvreDepartment of Digestive Surgery, Sorbonne University, Hôpital Saint-Antoine, AP-HP, Paris, France.

R CohenDepartment of Medical Oncology, Sorbonne University, Hôpital Saint-Antoine, AP-HP, Paris, France.

T AndréDepartment of Medical Oncology, Sorbonne University, Hôpital Saint-Antoine, AP-HP, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The optimal management of primary tumor (PT) in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors (ICIs) remains unclear. Patients and methods: We retrospectively analyzed a prospective, single-center cohort to assess PT outcomes in this setting. Results: Among 210 patients, 21% received first-line ICI; we focused on 33 patients (16%) without prior PT resection at ICI initiation. Early progressive disease (<6 months) occurred in 10 patients (5%), with eight deaths (<1 year); two underwent surgery for symptomatic PT. Among the remaining 23 patients (11%) with disease control (≥6 months), 15 had PT resection due to clinical events ( Conclusions: If PT is left in place at ICI initiation, close monitoring is required due to its specific evolution. Resection may be indicated for symptomatic stenosis. Prospective trials are needed to define the role of endoscopic monitoring and indication of PT resection in first-line ICI.

Indexed as

immune checkpoint inhibitorsmetastatic colorectal cancerMSI-Hprimary tumor resection

Identifiers

PMID41868055

DOI10.1016/j.esmogo.2026.100319

PMCPMC13000474

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.